Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
latest_posts
- 1
Quantum Computing’s Next Major Breakthroughs Could Come From Australia - 24 Sound blocking Earphones for Prevalent Sound and Solace
- 3Is relief in sight? Flu season still brutal but cases are declining.
- 4Famous Rough terrain Vehicles for 2024
- 5I visited the largest collection of public telescopes in the US in Oregon's high desert, and the dark skies blew me away
- Vaccine exemptions for religious or personal beliefs are rising across the U.S.
- Dominating Your Cash: The Fundamental Manual for Overseeing Individual accounting records
- German diesel hits new records over Easter weekend
- Scientists document a death from a meat allergy tied to certain ticks
- Little Urban areas to Visit in Western Europe
- Activists Took BMW and Mercedes to Court Over Gas Cars. It Didn’t Stick
- Manual for Picking the Ideal Wine Matching
- A 3-limbed Kemp's ridley sea turtle is now being tracked at sea by satellite
- Investigating Design and Individual Style: Track down Your Remarkable Look
